Novartis sues US government over Medicare drug price regulation
Reuters
Published Sep 01, 2023 04:23PM ET
Updated Sep 01, 2023 04:50PM ET
By Patrick Wingrove
(Reuters) - Swiss drugmaker Novartis (SIX:NOVN) on Friday said it had sued the U.S. government in an attempt to halt the Medicare drug-price negotiation program, which includes its top-selling heart-failure medicine Entresto.
The lawsuit, filed in federal court in New Jersey, is the first since the Biden administration on Tuesday released its list of 10 prescription medicines that will be subject to price negotiations by the Medicare health program, which covers 66 million people.
Other drugs selected were Bristol Myers (NYSE:BMY) Squibb and Pfizer’s blood thinner Eliquis, Merck's diabetes drug Januvia, and Eliquis rival Xarelto from Johnson & Johnson (NYSE:JNJ).
The Inflation Reduction Act, signed into law by President Joe Biden last year, allows Medicare to negotiate prices for some of its most costly drugs. The pharmaceutical industry says the program will curtail profits and compel it to pull back on developing new treatments.
Six other drugmakers, including Bristol Myers Squibb, J&J and Merck, had already sued the Centers for Medicare and Medicaid Services, which runs Medicare, before the drug list was announced in an effort to derail the price-setting process.
Novartis said in a written statement that the negotiations were unconstitutional because they amounted to a taking of private property and imposed excessive fines on manufacturers that refused to participate in the talks or accept the prices Medicare reached.
The other drugmakers made similar arguments in their lawsuits.
Get The News You Want
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.